Roger Abravanel - Teva Pharma Independent Director
| TEVA Stock | USD 12.88 0.02 0.16% |
Director
Mr. Roger Abravanel serves as Director at Teva Pharmaceutical Industries Limited since January 2007. He is a member of the Human Resources, Compensation, Corporationrationrate Governance, Nominating, Finance and Investment committees. His work experience includes the following roles Principal at McKinsey Company, Director at McKinsey Company, Provider of Consulting services to Israeli and Italian private and VC funds, Director of COFIDEGruppo De Benedetti SpA, Director at Luxottica Group SpA, Director at Admiral Group plc, Director at Banca Nazionale del Lavoro and Chairman of INSEADs Advisory Group in Italy since 2007.
| Age | 71 |
| Tenure | 17 years |
| Professional Marks | MBA |
| Address | 124 Dvora HaNevi?a Street, Tel Aviv, Israel, 6944020 |
| Phone | 972 3 914 8213 |
| Web | https://www.tevapharm.com |
Teva Pharma Management Efficiency
The company has return on total asset (ROA) of 0.0454 % which means that it generated a profit of $0.0454 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0736) %, meaning that it created substantial loss on money invested by shareholders. Teva Pharma's management efficiency ratios could be used to measure how well Teva Pharma manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.03. In addition to that, Return On Capital Employed is expected to decline to 0.01. At present, Teva Pharma's Non Currrent Assets Other are projected to decrease significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 914.4 M, whereas Total Assets are forecasted to decline to about 26.4 B.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Michael Graves | Eagle Pharmaceuticals | 61 | |
| Lynda Reid | Evotec SE ADR | N/A | |
| Grainne Troute | Evotec SE ADR | N/A | |
| Floyd Bloom | Alkermes Plc | 80 | |
| Hamish Stevens | Evotec SE ADR | N/A | |
| Norah Barlow | Evotec SE ADR | N/A | |
| Steven Ratoff | Eagle Pharmaceuticals | 81 | |
| Wendy Dixon | Alkermes Plc | 62 | |
| Paul Mitchell | Alkermes Plc | 64 | |
| Richard Edlin | Eagle Pharmaceuticals | 57 | |
| Nancy Snyderman | Alkermes Plc | 66 | |
| Robert Breyer | Alkermes Plc | 73 | |
| Douglas Braunstein | Eagle Pharmaceuticals | 57 | |
| Sander Flaum | Eagle Pharmaceuticals | 81 | |
| Anthony Quirk | Evotec SE ADR | N/A | |
| Edward Kay | Eagle Pharmaceuticals | N/A | |
| Robert Glenning | Eagle Pharmaceuticals | 57 | |
| Nancy Wysenski | Alkermes Plc | 60 | |
| David Pernock | Eagle Pharmaceuticals | 63 | |
| Alain Schreiber | Eagle Pharmaceuticals | 58 | |
| David Anstice | Alkermes Plc | 69 | |
Management Performance
| Return On Equity | -0.0736 | ||||
| Return On Asset | 0.0454 |
Teva Pharma Industries Leadership Team
Elected by the shareholders, the Teva Pharma's board of directors comprises two types of representatives: Teva Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Teva. The board's role is to monitor Teva Pharma's management team and ensure that shareholders' interests are well served. Teva Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Teva Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Moshe Many, Independent Director | ||
| Richard Daniell, Executive Vice President - European Commercial | ||
| Mark Sabag, Executive Vice President, Chief Human Resources Officer and Global Communications and Brand | ||
| Ronit SatchiFainaro, Independent Director | ||
| Richard Lerner, Independent Director | ||
| Galia Maor, Independent Director | ||
| Janet Vergis, Independent Director | ||
| Carlo Notaristefani, CEO of Global Operations and President of Global Operations | ||
| Richard Francis, CEO President | ||
| JeanMichel Halfon, Statutory - independent director | ||
| Eli Shani, Executive Vice President - Global Marketing and Portfolio | ||
| Dipankar Bhattacharjee, Senior Vice President CFO Americas and Head of Finance Operations | ||
| Abbas Hussain, Independent Director | ||
| Yitzhak Peterburg, Director | ||
| Hafrun Fridriksdottir, Executive Vice President and Presidentident of Global Generics R&D | ||
| Ran Meir, Head Relations | ||
| Perry Nisen, Independent Director | ||
| Isaac Abravanel, Group Executive Vice President Teva Corporate in Israel and Global Community Alliances, Director | ||
| David Stark, Executive Vice President, Chief Legal Officer | ||
| Tal Zaks, Independent Director | ||
| Amir Elstein, Vice Chairman of the Board | ||
| Dan Suesskind, Director | ||
| Arie Belldegrun, Independent Director | ||
| Richard Egosi, Chief Legal Officer and Group Executive VP | ||
| Andrew Weil, Chief Accounting Officer | ||
| Jean Halfon, Statutory - independent director | ||
| Sven Dethlefs, Executive Vice President - Global Marketing & Portfolio and International Markets Commercial | ||
| Robert Koremans, President CEO-Global Specialty Medicines | ||
| Dov Bergwerk, Acting Secretary | ||
| Gerald Lieberman, Independent Director | ||
| Roberto Mignone, Independent Director | ||
| Rosemary Crane, Independent Director | ||
| Nechemia Peres, Independent Director | ||
| Roger Abravanel, Independent Director | ||
| Eyal Desheh, CFO and Group Executive VP | ||
| Gianfranco Nazzi, Executive Vice President - International Markets Commercial | ||
| Kare Schultz, CEO Pres | ||
| Iris BeckCodner, Group Executive Vice President - Corporate Marketing Excellence and Communication | ||
| Amir Weiss, Senior Vice President Chief Accounting Officer | ||
| Brendan OGrady, Executive Vice President - North America Commercial | ||
| Michael Hayden, President - Global Research and Development, Chief Scientific Officer | ||
| Gabrielle Sulzberger, Statutory Independent Director | ||
| Galia Inbar, Executive Vice President - Global Communications, Brand and ESG, Chief Human Resource Officer | ||
| Eric Drape, Executive Vice President - Global Operations | ||
| Vikki Conway, Acting Resources | ||
| Erez Vigodman, CEO and President Director and Member of Fin. and Invesment Committee | ||
| Eliyahu Kalif, Chief Financial Officer, Executive Vice President | ||
| Kathleen Veit, Global President | ||
| Joseph Nitzani, Independent Director | ||
| Timothy Wright, Head - Business Development, Strategy and Innovation | ||
| Sigurdur Olafsson, CEO of Global Generic Medicines Group and President of Global Generic Medicines Group | ||
| Murray Goldberg, Independent Director | ||
| Dan Propper, Independent Director | ||
| Ory Slonim, Independent Director | ||
| Michael McClellan, CFO, Executive Vice President | ||
| Kevin Mannix, Head of Global Investor Relations and VP | ||
| Kaare Schultz, President, Chief Executive Officer, Director | ||
| Sol Barer, Independent Chairman of the Board |
Teva Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Teva Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0736 | ||||
| Return On Asset | 0.0454 | ||||
| Profit Margin | (0.04) % | ||||
| Operating Margin | 0.28 % | ||||
| Current Valuation | 32.11 B | ||||
| Shares Outstanding | 1.13 B | ||||
| Shares Owned By Institutions | 52.65 % | ||||
| Number Of Shares Shorted | 11.56 M | ||||
| Price To Earning | 15.67 X | ||||
| Price To Book | 1.99 X |
Teva Pharma Investors Sentiment
The influence of Teva Pharma's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Teva. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Teva Pharma's public news can be used to forecast risks associated with an investment in Teva. The trend in average sentiment can be used to explain how an investor holding Teva can time the market purely based on public headlines and social activities around Teva Pharma Industries. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Teva Pharma's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Teva Pharma's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Teva Pharma's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Teva Pharma.
Teva Pharma Implied Volatility | 51.33 |
Teva Pharma's implied volatility exposes the market's sentiment of Teva Pharma Industries stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Teva Pharma's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Teva Pharma stock will not fluctuate a lot when Teva Pharma's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Teva Pharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Teva Pharma's short interest history, or implied volatility extrapolated from Teva Pharma options trading.
Currently Active Assets on Macroaxis
When determining whether Teva Pharma Industries offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Teva Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Teva Pharma Industries Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Teva Pharma Industries Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Teva Pharma Industries. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Complementary Tools for Teva Stock analysis
When running Teva Pharma's price analysis, check to measure Teva Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Teva Pharma is operating at the current time. Most of Teva Pharma's value examination focuses on studying past and present price action to predict the probability of Teva Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Teva Pharma's price. Additionally, you may evaluate how the addition of Teva Pharma to your portfolios can decrease your overall portfolio volatility.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |
Is Teva Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Teva Pharma. If investors know Teva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Teva Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.4 | Earnings Share (0.50) | Revenue Per Share 14.161 | Quarterly Revenue Growth 0.148 | Return On Assets 0.0454 |
The market value of Teva Pharma Industries is measured differently than its book value, which is the value of Teva that is recorded on the company's balance sheet. Investors also form their own opinion of Teva Pharma's value that differs from its market value or its book value, called intrinsic value, which is Teva Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Teva Pharma's market value can be influenced by many factors that don't directly affect Teva Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Teva Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Teva Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Teva Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.